Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.mehy.2020.110005 http://scihub22266oqcxt.onion/10.1016/j.mehy.2020.110005 32575019!7297676!32575019     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Med+Hypotheses 2020 ; 144 (ä): 110005 Nephropedia Template TP {{tp|p=32575019|t=2020. Pirfenidone: A novel hypothetical treatment for COVID-19 |pdf=|usr=}}{{32575019}} gab.com Text Pirfenidone: A novel hypothetical treatment for COVID-19 JO: Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=32575019 #FOAvip Cytokine storm, multiorgan failure, and particularly acute respiratory distress syndrome (ARDS) is the leading cause of mortality and morbidity in patients with COVID-19. A fulminant ARDS kills the majority of COVID-19 victims. Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), is a novel anti-fibrotic agent with trivial adverse effects. Pirfenidone is approved for the treatment of Idiopathic Pulmonary Fibrosis (IPF) for patients with mild to moderate disease. Pirfenidone could inhibit apoptosis, downregulate ACE receptors expression, decrease inflammation by several mechanisms and ameliorate oxidative stress and hence protect pneumocytes and other cells from COVID-19 invasion and cytokine storm simultaneously. Based on the pirfenidone mechanism of action and the known pathophysiology of COVID-19, I believe that pirfenidone has the potential for the treatment of COVID-19 patients. Twit Text FOAVip Pirfenidone: A novel hypothetical treatment for COVID-19 ????Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=32575019 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32575019 #FOAvip English Wikipedia <ref>{{Cite pmid|32575019}}</ref> Pirfenidone: A novel hypothetical treatment for COVID-19 #MMPMID32575019 Seifirad S Med Hypotheses 2020[Nov]; 144 (ä): 110005 PMID32575019show ga Cytokine storm, multiorgan failure, and particularly acute respiratory distress syndrome (ARDS) is the leading cause of mortality and morbidity in patients with COVID-19. A fulminant ARDS kills the majority of COVID-19 victims. Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), is a novel anti-fibrotic agent with trivial adverse effects. Pirfenidone is approved for the treatment of Idiopathic Pulmonary Fibrosis (IPF) for patients with mild to moderate disease. Pirfenidone could inhibit apoptosis, downregulate ACE receptors expression, decrease inflammation by several mechanisms and ameliorate oxidative stress and hence protect pneumocytes and other cells from COVID-19 invasion and cytokine storm simultaneously. Based on the pirfenidone mechanism of action and the known pathophysiology of COVID-19, I believe that pirfenidone has the potential for the treatment of COVID-19 patients. |*COVID-19 Drug Treatment[MESH] |*Drug Repositioning[MESH] |Alveolar Epithelial Cells/drug effects[MESH] |Angiotensin-Converting Enzyme 2/biosynthesis/genetics[MESH] |Animals[MESH] |Anti-Inflammatory Agents/pharmacology/*therapeutic use[MESH] |Apoptosis/drug effects[MESH] |COVID-19/complications[MESH] |Cytokine Release Syndrome/etiology/prevention & control[MESH] |Disease Models, Animal[MESH] |Down-Regulation/drug effects[MESH] |Humans[MESH] |Lipid Peroxidation/drug effects[MESH] |Oxidative Stress/drug effects[MESH] |Pyridones/pharmacology/*therapeutic use[MESH]Pirfenidone: A novel hypothetical treatment for COVID-19 (epmc).pdf DeepDyve Pubget Overpricing